Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

SYRS Syros Pharmaceuticals Inc

1,95

-0,05 (-2,50%)

Zuletzt aktualisiert: 17:32:01

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024

Click Here for more Syros Pharmaceuticals Charts.

Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024

Click Here for more Syros Pharmaceuticals Charts.

News Syros Pharmaceuticals Inc

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 12 September 2024 (6 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 5 September 2024 (2 Wochen vor) • Edgar (US Regulatory)

Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Dienstag 27 August 2024 (3 Wochen vor) • Business Wire

Form 8-K - Current report
Montag 12 August 2024 (1 Monat vor) • Edgar (US Regulatory)

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Montag 12 August 2024 (1 Monat vor) • Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Samstag 3 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Mittwoch 31 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
Mittwoch 31 Juli 2024 (2 Monate vor) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 31 Juli 2024 (2 Monate vor) • Edgar (US Regulatory)

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Mittwoch 24 Juli 2024 (2 Monate vor) • Business Wire

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Donnerstag 13 Juni 2024 (3 Monate vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Syros Pharmaceuticals Inc News-Artikel

Health Care Select Sector

Euro vs Sterling

BNP Paribas (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen